Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 24Colorectal Neoplasms 16Small Cell Lung Carcinoma 6Stomach Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Rectal Neoplasms 3Osteosarcoma 3Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Cancer × irinotecan sucrosofate × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡